Cargando…

Advancing Precision Vaccinology by Molecular and Genomic Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 in Germany, 2021( )

BACKGROUND: Comprehensive pathogen genomic surveillance represents a powerful tool to complement and advance precision vaccinology. The emergence of the Alpha variant in December 2020 and the resulting efforts to track the spread of this and other severe acute respiratory syndrome coronavirus 2 (SAR...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Djin Ye, Hölzer, Martin, Paraskevopoulou, Sofia, Trofimova, Maria, Hartkopf, Felix, Budt, Matthias, Wedde, Marianne, Richard, Hugues, Haldemann, Berit, Domaszewska, Teresa, Reiche, Janine, Keeren, Kathrin, Radonić, Aleksandar, Ramos Calderón, Julia Patricia, Smith, Maureen Rebecca, Brinkmann, Annika, Trappe, Kathrin, Drechsel, Oliver, Klaper, Kathleen, Hein, Sascha, Hildt, Eberhardt, Haas, Walter, Calvignac-Spencer, Sébastien, Semmler, Torsten, Dürrwald, Ralf, Thürmer, Andrea, Drosten, Christian, Fuchs, Stephan, Kröger, Stefan, von Kleist, Max, Wolff, Thorsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278222/
https://www.ncbi.nlm.nih.gov/pubmed/35749674
http://dx.doi.org/10.1093/cid/ciac399
_version_ 1784746146845949952
author Oh, Djin Ye
Hölzer, Martin
Paraskevopoulou, Sofia
Trofimova, Maria
Hartkopf, Felix
Budt, Matthias
Wedde, Marianne
Richard, Hugues
Haldemann, Berit
Domaszewska, Teresa
Reiche, Janine
Keeren, Kathrin
Radonić, Aleksandar
Ramos Calderón, Julia Patricia
Smith, Maureen Rebecca
Brinkmann, Annika
Trappe, Kathrin
Drechsel, Oliver
Klaper, Kathleen
Hein, Sascha
Hildt, Eberhardt
Haas, Walter
Calvignac-Spencer, Sébastien
Semmler, Torsten
Dürrwald, Ralf
Thürmer, Andrea
Drosten, Christian
Fuchs, Stephan
Kröger, Stefan
von Kleist, Max
Wolff, Thorsten
author_facet Oh, Djin Ye
Hölzer, Martin
Paraskevopoulou, Sofia
Trofimova, Maria
Hartkopf, Felix
Budt, Matthias
Wedde, Marianne
Richard, Hugues
Haldemann, Berit
Domaszewska, Teresa
Reiche, Janine
Keeren, Kathrin
Radonić, Aleksandar
Ramos Calderón, Julia Patricia
Smith, Maureen Rebecca
Brinkmann, Annika
Trappe, Kathrin
Drechsel, Oliver
Klaper, Kathleen
Hein, Sascha
Hildt, Eberhardt
Haas, Walter
Calvignac-Spencer, Sébastien
Semmler, Torsten
Dürrwald, Ralf
Thürmer, Andrea
Drosten, Christian
Fuchs, Stephan
Kröger, Stefan
von Kleist, Max
Wolff, Thorsten
author_sort Oh, Djin Ye
collection PubMed
description BACKGROUND: Comprehensive pathogen genomic surveillance represents a powerful tool to complement and advance precision vaccinology. The emergence of the Alpha variant in December 2020 and the resulting efforts to track the spread of this and other severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern led to an expansion of genomic sequencing activities in Germany. METHODS: At Robert Koch Institute (RKI), the German National Institute of Public Health, we established the Integrated Molecular Surveillance for SARS-CoV-2 (IMS-SC2) network to perform SARS-CoV-2 genomic surveillance at the national scale, SARS-CoV-2–positive samples from laboratories distributed across Germany regularly undergo whole-genome sequencing at RKI. RESULTS: We report analyses of 3623 SARS-CoV-2 genomes collected between December 2020 and December 2021, of which 3282 were randomly sampled. All variants of concern were identified in the sequenced sample set, at ratios equivalent to those in the 100-fold larger German GISAID sequence dataset from the same time period. Phylogenetic analysis confirmed variant assignments. Multiple mutations of concern emerged during the observation period. To model vaccine effectiveness in vitro, we employed authentic-virus neutralization assays, confirming that both the Beta and Zeta variants are capable of immune evasion. The IMS-SC2 sequence dataset facilitated an estimate of the SARS-CoV-2 incidence based on genetic evolution rates. Together with modeled vaccine efficacies, Delta-specific incidence estimation indicated that the German vaccination campaign contributed substantially to a deceleration of the nascent German Delta wave. CONCLUSIONS: SARS-CoV-2 molecular and genomic surveillance may inform public health policies including vaccination strategies and enable a proactive approach to controlling coronavirus disease 2019 spread as the virus evolves.
format Online
Article
Text
id pubmed-9278222
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-92782222022-07-18 Advancing Precision Vaccinology by Molecular and Genomic Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 in Germany, 2021( ) Oh, Djin Ye Hölzer, Martin Paraskevopoulou, Sofia Trofimova, Maria Hartkopf, Felix Budt, Matthias Wedde, Marianne Richard, Hugues Haldemann, Berit Domaszewska, Teresa Reiche, Janine Keeren, Kathrin Radonić, Aleksandar Ramos Calderón, Julia Patricia Smith, Maureen Rebecca Brinkmann, Annika Trappe, Kathrin Drechsel, Oliver Klaper, Kathleen Hein, Sascha Hildt, Eberhardt Haas, Walter Calvignac-Spencer, Sébastien Semmler, Torsten Dürrwald, Ralf Thürmer, Andrea Drosten, Christian Fuchs, Stephan Kröger, Stefan von Kleist, Max Wolff, Thorsten Clin Infect Dis Precision Vaccines Supplement BACKGROUND: Comprehensive pathogen genomic surveillance represents a powerful tool to complement and advance precision vaccinology. The emergence of the Alpha variant in December 2020 and the resulting efforts to track the spread of this and other severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern led to an expansion of genomic sequencing activities in Germany. METHODS: At Robert Koch Institute (RKI), the German National Institute of Public Health, we established the Integrated Molecular Surveillance for SARS-CoV-2 (IMS-SC2) network to perform SARS-CoV-2 genomic surveillance at the national scale, SARS-CoV-2–positive samples from laboratories distributed across Germany regularly undergo whole-genome sequencing at RKI. RESULTS: We report analyses of 3623 SARS-CoV-2 genomes collected between December 2020 and December 2021, of which 3282 were randomly sampled. All variants of concern were identified in the sequenced sample set, at ratios equivalent to those in the 100-fold larger German GISAID sequence dataset from the same time period. Phylogenetic analysis confirmed variant assignments. Multiple mutations of concern emerged during the observation period. To model vaccine effectiveness in vitro, we employed authentic-virus neutralization assays, confirming that both the Beta and Zeta variants are capable of immune evasion. The IMS-SC2 sequence dataset facilitated an estimate of the SARS-CoV-2 incidence based on genetic evolution rates. Together with modeled vaccine efficacies, Delta-specific incidence estimation indicated that the German vaccination campaign contributed substantially to a deceleration of the nascent German Delta wave. CONCLUSIONS: SARS-CoV-2 molecular and genomic surveillance may inform public health policies including vaccination strategies and enable a proactive approach to controlling coronavirus disease 2019 spread as the virus evolves. Oxford University Press 2022-06-25 /pmc/articles/PMC9278222/ /pubmed/35749674 http://dx.doi.org/10.1093/cid/ciac399 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Precision Vaccines Supplement
Oh, Djin Ye
Hölzer, Martin
Paraskevopoulou, Sofia
Trofimova, Maria
Hartkopf, Felix
Budt, Matthias
Wedde, Marianne
Richard, Hugues
Haldemann, Berit
Domaszewska, Teresa
Reiche, Janine
Keeren, Kathrin
Radonić, Aleksandar
Ramos Calderón, Julia Patricia
Smith, Maureen Rebecca
Brinkmann, Annika
Trappe, Kathrin
Drechsel, Oliver
Klaper, Kathleen
Hein, Sascha
Hildt, Eberhardt
Haas, Walter
Calvignac-Spencer, Sébastien
Semmler, Torsten
Dürrwald, Ralf
Thürmer, Andrea
Drosten, Christian
Fuchs, Stephan
Kröger, Stefan
von Kleist, Max
Wolff, Thorsten
Advancing Precision Vaccinology by Molecular and Genomic Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 in Germany, 2021( )
title Advancing Precision Vaccinology by Molecular and Genomic Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 in Germany, 2021( )
title_full Advancing Precision Vaccinology by Molecular and Genomic Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 in Germany, 2021( )
title_fullStr Advancing Precision Vaccinology by Molecular and Genomic Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 in Germany, 2021( )
title_full_unstemmed Advancing Precision Vaccinology by Molecular and Genomic Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 in Germany, 2021( )
title_short Advancing Precision Vaccinology by Molecular and Genomic Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 in Germany, 2021( )
title_sort advancing precision vaccinology by molecular and genomic surveillance of severe acute respiratory syndrome coronavirus 2 in germany, 2021( )
topic Precision Vaccines Supplement
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278222/
https://www.ncbi.nlm.nih.gov/pubmed/35749674
http://dx.doi.org/10.1093/cid/ciac399
work_keys_str_mv AT ohdjinye advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT holzermartin advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT paraskevopoulousofia advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT trofimovamaria advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT hartkopffelix advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT budtmatthias advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT weddemarianne advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT richardhugues advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT haldemannberit advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT domaszewskateresa advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT reichejanine advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT keerenkathrin advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT radonicaleksandar advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT ramoscalderonjuliapatricia advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT smithmaureenrebecca advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT brinkmannannika advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT trappekathrin advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT drechseloliver advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT klaperkathleen advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT heinsascha advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT hildteberhardt advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT haaswalter advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT calvignacspencersebastien advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT semmlertorsten advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT durrwaldralf advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT thurmerandrea advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT drostenchristian advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT fuchsstephan advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT krogerstefan advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT vonkleistmax advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT wolffthorsten advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021
AT advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021